Deciphera Pharmaceuticals,根据NASDAQ规则5635(c)(4)宣布诱因赠款

一家生物制药公司Deciphera Pharmaceuticals,Inc。致力于发现,开发和商业化重要的新药物以改善癌症患者的生活,宣布与雇用Lisa Amaya Price,高级副总裁兼首席人力资源官,首席人力资源官,the Compensation Committee of Deciphera’s Board of Directors approved the grant of a stock option to purchase 100,000 shares of Deciphera’s common stock and 25,000 restricted stock units (“RSUs”) to Ms. Amaya Price with a grant date of August 15, 2022.

另请阅读:Zonit推出了世界上最好的自动转移开关,用于工业和商业应用

该股权奖是根据该公司的2022诱导计划授予的,并根据纳斯达克上市规则5635(c)(4)授予。赠款是Amaya女士在公司接受就业的诱因材料。The options have a ten-year term, and the exercise price of the options is $16.64, equal to the fair market value of the Company’s common stock on the Nasdaq on August 15, 2022. The shares subject to the option vest over a four-year period, with 25 percent of the shares subject to the option vesting on the first anniversary of Ms. Amaya Price’s date of hire and the remainder vesting in equal monthly installments over three years thereafter. The 25,000 shares underlying the RSU grant will vest in equal annual installments over a three-year period, beginning on or about the one-year anniversary of the grant date. The awards are subject to the terms and conditions of their applicable equity award agreements, including having a continued relationship with the Company on the vesting date.

Deciphera是一家生物制药公司,致力于发现,开发和商业化重要的新药物,以改善癌症患者的生活。我们正在利用专有的开关控制激酶抑制剂平台和激酶生物学的深入专业知识来开发广泛的创新药物组合。除了从我们的临床研究平台上推进多个候选产品外,Qinlock®还是Deciphera的开关控制抑制剂,用于治疗第四线要点。Qinlock在澳大利亚,加拿大,中国,欧盟,香港,瑞士,台湾,英国和美国批准。

现在订阅

    热点话题

    Baidu
    map